Heavy menstrual bleeding (HMB) is one of the most common reasons women see a clinician for gynecologic concerns, and one of the most under-diagnosed. The frequent message — that heavy periods are normal, just deal with it — has been formally rejected by both ACOG (Practice Bulletin 226, 2020) and NICE (NG88, 2018). HMB is defined by impact: bleeding that interferes with physical, social, emotional, or material quality of life. There is no requirement to “prove” heaviness through milliliter measurement before being taken seriously.
This post covers how HMB is defined, what causes it, what evaluation should look like, and the treatment options that actually work.
What HMB is
Older definitions (more than 80 mL per cycle) came from research lab studies measuring blood loss directly. They are scientifically useful but clinically impractical — almost no one measures period blood by volume.
Modern guidelines define HMB by patient-reported impact:
- Soaking through a pad or tampon every 1 to 2 hours.
- Bleeding lasting more than 7 days.
- Passing clots larger than a 25-cent coin (quarter, 25mm).
- Needing to use two products at once or change products at night.
- Restricting activities, missing work or school.
- Symptoms of iron deficiency: fatigue, dizziness, hair loss, exercise intolerance.
Tools like the Pictorial Blood Loss Assessment Chart (PBAC) are sometimes used to semi-quantify bleeding by counting product use and clot frequency over a cycle. Scores above 100 correlate with measured blood loss above 80 mL. PBAC is mostly used in research and specialized clinics.
What causes HMB
The PALM-COEIN classification (FIGO 2011, updated since) groups causes into structural and non-structural:
PALM (structural, usually visible on imaging):
- Polyps: endometrial growths.
- Adenomyosis: endometrial tissue within the uterine muscle wall.
- Leiomyoma (fibroids): benign muscular tumors.
- Malignancy and hyperplasia: endometrial cancer or precancer.
COEIN (non-structural):
- Coagulopathy: bleeding disorders. Von Willebrand disease is found in roughly 10 to 20 percent of adolescents and adults with HMB.
- Ovulatory dysfunction: anovulation, common in perimenopause and PCOS.
- Endometrial: local endometrial issues (rare and often diagnosis of exclusion).
- Iatrogenic: medications (anticoagulants, hormonal IUD removal, copper IUD, certain contraceptive switches).
- Not yet classified.
Adenomyosis and fibroids together account for a large fraction of HMB in women over 30. Anovulatory bleeding (often heavy, often unpredictable) is common in adolescents and in perimenopause. Bleeding disorders are systematically underscreened — easy to miss without a deliberate question.
The evaluation pathway
A structured HMB workup looks like:
1. History
- Age of menarche.
- Cycle length, period duration, current pattern, recent change.
- Bleeding between periods or after sex.
- Pain (severity, timing).
- Personal and family history of bleeding (heavy bleeds with surgery, dental work, postpartum, bruising easily).
- Pregnancy desire, current contraception, current medications.
2. Physical exam
- General including signs of anemia (pallor, tachycardia).
- Pelvic exam: uterine size and tenderness, cervical exam, adnexal exam.
3. Initial labs
- Pregnancy test. First and always, for any abnormal bleeding.
- CBC and ferritin. Hemoglobin shows current anemia; ferritin shows iron stores. Ferritin is often skipped but is the more sensitive test for iron deficiency.
- TSH. Thyroid disease is a classic mimic. See thyroid and menstrual cycles.
- Bleeding disorder screen in adolescents, in anyone with HMB since menarche, or family history of bleeding (von Willebrand panel, PT, aPTT, fibrinogen).
4. Imaging
- Pelvic ultrasound (transvaginal preferred) is first-line for evaluating fibroids, adenomyosis, polyps, ovarian pathology.
- Saline-infusion sonography (SIS) or hysteroscopy when ultrasound is non-diagnostic for an endometrial polyp or submucosal fibroid.
- MRI in selected cases when ultrasound is limited or surgery is being planned.
5. Endometrial sampling
Endometrial biopsy is recommended for:
- Women age 45 or older with HMB.
- Younger women with risk factors (obesity, PCOS, unopposed estrogen exposure, Lynch syndrome family history, persistent intermenstrual bleeding).
This rules out hyperplasia and endometrial cancer.
What treatment looks like
Treatment depends on cause, age, contraceptive needs, and pregnancy plans.
Medical treatment (first-line for most)
- Levonorgestrel intrauterine device (LNG-IUD). The most effective medical therapy for HMB. Reduces bleeding by 70 to 95 percent over 6 to 12 months and is the first-line option in NICE guidance for most causes (excluding submucosal fibroids).
- Combined hormonal contraceptives (pill, patch, ring). Reduce bleeding 30 to 50 percent. Useful when cycle suppression and contraception are both desired.
- Tranexamic acid. Antifibrinolytic taken during periods only; reduces bleeding 30 to 50 percent. No hormonal effects. Good for people who want effective treatment without changing cycle hormones.
- NSAIDs (mefenamic acid, naproxen) taken during periods reduce bleeding 20 to 30 percent and also help cramping.
- Progestin-only options (norethindrone, depot medroxyprogesterone) are alternatives.
Iron supplementation runs alongside any bleeding treatment if ferritin is low. Stoffel et al. (Lancet Haematology 2017) showed every-other-day dosing is at least as effective as daily and better tolerated.
Procedural and surgical
- Endometrial ablation for women who have completed childbearing.
- Myomectomy for fibroids when fertility preservation is wanted.
- Uterine artery embolization as a non-surgical option for fibroids.
- Hysterectomy as definitive treatment when other options fail or are inappropriate.
The right choice depends on cause, severity, age, fertility plans, and personal preference.
What to track and bring to the visit
Three to six months of cycle data is the most useful single thing you can bring:
- Period start and end dates.
- Heaviest days, product change frequency, presence of clots.
- Pain ratings.
- Energy level, especially during and after periods.
The Period Calculator makes this simple. You can also bring a PBAC-style log if your clinic provides one.
Common patterns and what they suggest
- Sudden new HMB after years of normal periods. Think structural (fibroid, polyp, adenomyosis) or hormonal change (perimenopause, contraceptive switch). Rarely, malignancy.
- HMB since menarche. Higher index of suspicion for bleeding disorder (especially von Willebrand) — push for the screen.
- HMB plus severe pain plus dyspareunia. Consider endometriosis or adenomyosis. See endometriosis and cycles.
- HMB plus irregular cycles. Anovulatory bleeding — common in PCOS and perimenopause.
- HMB plus fatigue out of proportion to bleeding. Check thyroid and ferritin.
Iron deficiency: the hidden cost
Many women with HMB have unaddressed iron deficiency. Symptoms — fatigue, brain fog, restless legs, hair shedding, exercise intolerance — are often blamed on stress, age, or “just being a woman.” Ferritin under 30 ng/mL signals iron deficiency even with a normal hemoglobin.
Treating iron deficiency, even before treating the bleeding cause, often produces a noticeable quality-of-life improvement within weeks. Oral iron is first-line. IV iron is appropriate for severe deficiency, intolerance to oral iron, or surgical preparation.
Questions worth asking
- Have I had a CBC and ferritin within the last 6 to 12 months?
- Do I need a pelvic ultrasound?
- Should I be screened for a bleeding disorder?
- Am I a candidate for the levonorgestrel IUD?
- If I want a non-hormonal option, is tranexamic acid right for me?
The bottom line
Heavy menstrual bleeding is defined by impact, not measurement. It is common, treatable, and under-investigated. The pathway is straightforward: history, pregnancy test, CBC and ferritin, TSH, ultrasound, and structured treatment based on cause. The hormonal IUD remains the single most effective medical option for most causes. If your bleeding affects your life, you have not just earned care, you are entitled to it.